Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation—a novel mechanism for the cardioprotective effects of PPAR agonists - Liu, H-R; Tao, L; Gao, E (Cardiovasc Res, 2009)
, et al.